Correction to: Int J Retin Vitr (2017) 3:22 DOI 10.1186/s40942-017-0075-x
After the publication of this article [1], we were made aware that the osmolarity of aflibercept (Eylea) was incorrect and should have been 286 mOsm and not 1000 mOsm. The correct version of Table 1 is shown in this correction (Table 1).
Table 1.
The formulations and pH values of anti-VEGF agents
| Drug | Concentration (osmolarity) | Dose in the vitreous (4 ml)/dose in 0.002 ml | Formulation | Measured pH | 95% CI |
|---|---|---|---|---|---|
| Ranibizumab (Lucentis) | 10 mg/ml (289 mOsm) | 0.5 mg/0.02 mg | 10 mM histidine-HCl, 10% α,α-trehalose dihydrate, 0.01% polysorbate 20 | 5.32 | 5.0–5.63 |
| Bevacizumab (Avastin) | 25 mg/ml (182 mOsm) | 1.25 mg/0.05 mg | 42 mM NaH2PO4·H2O, 8.45 mM Na2HPO4, 6% α,α-trehalose dihydrate, 0.04% polysorbate 20 | 5.91 | 5.63–6.19 |
| Aflibercept (Eylea) | 40 mg/ml (286 mOsm) | 2 mg/0.08 mg | 10 mM Na3PO4, 40 mM NaCl, 5% sucrose, 0.03% polysorbate 20 | 6.05 | 5.78–6.31 |
| Ziv-aflibercept (Zaltrap) | 25 mg/ml (1000 mOsm) | 1.25 mg/0.05 mg | 100 mM NaCl, 5 mM Na citrate, 5 mM Na3PO4, 20% sucrose, 0.1% polysorbate 20 | 6.1 | 6.05–6.15 |
| Rituximab (Rituxan) | 10 mg/ml | 1 mg/0.02 mg | 154 mM NaCl, 25 mM Na citrate·2 H2O, 0.07% polysorbate 80 | 6.29 | 5.97–6.61 |
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Footnotes
The online version of the original article can be found under doi:10.1186/s40942-017-0075-x.
Contributor Information
Bianka Sobolewska, Phone: +49-7071-2988088, Email: bianka.sob@gmx.de.
Peter Heiduschka, Email: peter.heiduschka@ukmuenster.de.
Karl‑Ulrich Bartz‑Schmidt, Email: U.Bartz-Schmidt@uni-tuebingen.de.
Focke Ziemssen, Email: Focke.Ziemssen@med.uni-tuebingen.de.
Reference
- 1.Sobolewska B, et al. pH of anti-VEGF agents in the human vitreous: low impact of very different formulations. Int J Retin Vitr. 2017;3:22. doi: 10.1186/s40942-017-0075-x. [DOI] [PMC free article] [PubMed] [Google Scholar]